Protalix Biotherapeutics, Inc. quarterly report, Q2 FY2005

Business Context and Reporting Period

This Form 10-QSB covers the quarterly period ended June 30, 2005, for Orthodontix, Inc. (Note: The input metadata referenced Protalix Biotherapeutics, but the filing text explicitly identifies the issuer as Orthodontix, Inc.). The Company is a shell entity that terminated its affiliation with its founding orthodontic practices in 2001. It currently has no active operating business and is devoting its resources to identifying and consummating a merger or acquisition with an operating company.

Key Financial Metrics

Metric Three Months Ended June 30, 2005 Six Months Ended June 30, 2005
Revenue $0 $0
Net Loss $(12,776) $(23,135)
Loss Per Share (Basic & Diluted) $(0.00) $(0.01)
General & Administrative Expenses $20,445 $31,308
Interest and Other Income $7,669 $8,173
Cash and Cash Equivalents (End of Period) $515,153
Total Liabilities $57,785
Accumulated Deficit $(3,760,887)
Shares Outstanding 2,915,428

Material Changes vs. Prior Period

  • Net Loss Reduction: The net loss for the three months ended June 30, 2005, decreased significantly to $(12,776) compared to $(58,543) in the same period in 2004. Similarly, the six-month net loss decreased to $(23,135) from $(85,236) in the prior year.
  • Expense Reduction: General and administrative expenses dropped to $20,445 for the quarter (from $59,908 in 2004) and $31,308 for the six months (from $89,592 in 2004).
  • Income Increase: Total other income increased to $7,669 for the quarter (from $1,365 in 2004), driven primarily by interest income and other income.
  • Cash Flow: Net cash used in operating activities for the six months ended June 30, 2005, was $(48,559), a significant improvement compared to $(109,695) in the prior year period.

Outlook, Risks, and Management Commentary

  • Plan of Operation: Management intends to continue seeking a business combination with an operating company in industries such as aircraft maintenance, health care, pharmaceuticals, or financial services. No specific target or contractual commitment exists.
  • Liquidity: The Company holds approximately $515,200 in cash, primarily in money market accounts. Management believes this is sufficient to fund operations for at least the next twelve months.
  • Risks: There is no assurance that the Company will successfully consummate a merger or acquisition, or that the combined entity would be profitable. The Company has an accumulated deficit of over $3.7 million.
  • Controls: Management concluded that disclosure controls and procedures were effective as of June 30, 2005, with no significant changes in internal controls.
  • Legal Proceedings: None reported.

Investor Verification Checklist

  • Verify the Company's current cash balance of ~$515k against recent bank statements to confirm liquidity runway.
  • Confirm the absence of any undisclosed agreements or negotiations regarding a potential merger or acquisition.
  • Review the "Accumulated Deficit" of $3.76M to understand the historical capital consumption.
  • Check for any new filings (8-K) post-August 9, 2005, regarding changes in management or strategic direction.
  • Validate the concentration risk regarding bank deposits, noting $378,455 was held in excess of federally insured limits.